The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of EMD 525797 (DI17E6), an antibody targeting ανβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer.
Elena Elez
No relevant relationships to disclose
Ilona Kocáková
No relevant relationships to disclose
Thomas Hoehler
No relevant relationships to disclose
Uwe Marc Martens
No relevant relationships to disclose
Carsten Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Eric Van Cutsem
Research Funding - Merck Serono
Robert J Fram
Employment or Leadership Position - EMD Serono
Laurence Bernard
Employment or Leadership Position - Merck Serono
Josep Tabernero
Consultant or Advisory Role - Amgen; Amgen; Genentech; Genentech; Merck Serono; Merck Serono; Roche; Roche; Sanofi ; Sanofi
Honoraria - Amgen; Merck Serono; Roche; Sanofi